INCY Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Incyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.84 |
| 52 Week High | US$83.95 |
| 52 Week Low | US$50.35 |
| Beta | 0.70 |
| 1 Month Change | -3.11% |
| 3 Month Change | 4.72% |
| 1 Year Change | 9.53% |
| 3 Year Change | -6.30% |
| 5 Year Change | -22.12% |
| Change since IPO | 3,571.47% |
Recent News & Updates
Recent updates
Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Oct 31Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Aug 19Incyte: The Worst Has Been Avoided
Jun 16It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year
Jun 06
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings
May 07Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)
May 03Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27Knight's affiliate files for Brazilian approval of cancer drug tafasitamab
Oct 07Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
Sep 29Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia
Sep 15Incyte wins approval of Pemazyre for rare blood cancer
Aug 26Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%
Aug 02Incyte Corp. Should Move Higher (Technical Analysis)
Jul 18Incyte: Growth Drivers Are Coming
Jun 17Shareholder Returns
| INCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | -3.6% | -2.4% |
| 1Y | 9.5% | -2.7% | 23.3% |
Return vs Industry: INCY exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: INCY underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| INCY volatility | |
|---|---|
| INCY Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INCY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INCY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,524 | Herve Hoppenot | www.incyte.com |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.
Incyte Corporation Fundamentals Summary
| INCY fundamental statistics | |
|---|---|
| Market cap | US$12.92b |
| Earnings (TTM) | US$32.48m |
| Revenue (TTM) | US$4.08b |
408.3x
P/E Ratio3.3x
P/S RatioIs INCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INCY income statement (TTM) | |
|---|---|
| Revenue | US$4.08b |
| Cost of Revenue | US$2.88b |
| Gross Profit | US$1.20b |
| Other Expenses | US$1.16b |
| Earnings | US$32.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 29.33% |
| Net Profit Margin | 0.80% |
| Debt/Equity Ratio | 0% |
How did INCY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:48 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Incyte Corporation is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Thomas Russo | Baird |
| Ishan Majumdar | Baptista Research |